摘要
目的探讨miR-124与人类白细胞抗原G(HLA-G)在宫颈癌中的表达及变化。方法选取2018年1月至2019年1月该院住院治疗的65例宫颈癌患者作为研究组,另选取同期在该院进行子宫肌瘤切除的40例患者作为对照组,通过实时荧光定量PCR检测宫颈组织中miR-124相对表达水平,采用化学发光免疫检测血清HLA-G水平,观察miR-124与HLA-G在宫颈癌中的表达及变化。结果研究组宫颈组织中miR-124相对表达水平低于对照组,研究组血清HLA-G水平高于对照组,差异均有统计学意义(P<0.05);研究组宫颈组织中miR-124相对表达水平在国际妇产科联盟(FIGO)分期、淋巴结转移、腺体浸润及脉管浸润间比较,差异有统计学意义(P<0.05);而血清HLA-G水平在FIGO分期、淋巴结转移、脉管浸润间比较,差异有统计学意义(P<0.05)。miR-124与HLA-G联合检测的灵敏度为87.18%,特异度为83.52%。结论miR-124与HLA-G水平变化与宫颈癌FIGO分期、淋巴结转移及脉管浸润有关,二者联合检测有望成为宫颈癌诊断的新靶点。
Objective To investigate the expression and changes of miR-124 and human leukocyte antigen-G(HLA-G)in cervical cancer.Methods From January 2018 to January 2019,65 patients with cervical cancer hospitalized in a hospital were selected as the study group,and 40 patients of hysteromyomectomy in a hospital during the same period were selected as the control group.The relative expression level of miR-124 in cervical tissue was detected by real-time fluorescence quantitative PCR,and HLA-G level in serum was detected by chemiluminescence immunoassay to observe the expression and changes of miR-124 and HLA-G in cervical cancer.Results The relative expression level of miR-124 in cervical tissue of the study group was lower than that of the control group,and the level of HLA-G in serum of the study group was higher than that of the control group,with statistical significance(P<0.05).The relative expression level of miR-124 in the cervical tissues of the study group was significantly different among the international federation of gynecology and obstetrics(FIGO)staging,lymph node metastasis,gland infiltration and vascular infiltration(P<0.05).The difference of serum HLA-G level among FIGO staging,lymph node metastasis and vascular infiltration was statistically significant(P<0.05).The sensitivity and specificity of miR-124 combined with HLA-G were 87.18%and 83.52%respectively.Conclusion The changes of miR-124 and HLA-G levels are related to the FIGO staging,lymph node metastasis and vascular invasion of cervical cancer.The combined detection of the two is expected to become a new target for the diagnosis of cervical cancer.
作者
陶国华
谢玮
李荔
TAO Guohua;XIE Wei;LI Li(Department of Clinical Laboratory,Nantong First People′s Hospital,Nantong,Jiangsu 226001,China)
出处
《检验医学与临床》
CAS
2021年第12期1677-1680,共4页
Laboratory Medicine and Clinic